Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fusion Pharmaceuticals Inc
(NQ:
FUSN
)
21.55
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Fusion Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024
May 07, 2024
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Top 4 Health Care Stocks That May Plunge This Month
April 26, 2024
Via
Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA...
Via
Benzinga
Exposures
Product Safety
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
April 02, 2024
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over...
Via
Benzinga
Recap: Fusion Pharmaceuticals Q4 Earnings
March 20, 2024
Via
Benzinga
Unveiling 11 Analyst Insights On Fusion Pharmaceuticals
March 20, 2024
Via
Benzinga
Kuehn Law Encourages FUSN, KAMN, DRQ, and VZIO Investors to Contact Law Firm
March 19, 2024
--News Direct--
Via
News Direct
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023
March 20, 2024
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
March 19, 2024
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow traded up 0.63% to 39,034.59 while the NASDAQ rose 0.35% to 16,160.20. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
Via
Benzinga
A Glimpse Into The Expert Outlook On Fusion Pharmaceuticals Through 7 Analysts
March 04, 2024
Via
Benzinga
Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts
January 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
March 19, 2024
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.54% to 39,001.22 while the NASDAQ fell 0.34% to 16,048.51. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down 100 Points; US Housing Starts Surge In February
March 19, 2024
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 19, 2024
Via
Benzinga
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
March 19, 2024
The company is working on radiopharmaceuticals treatments for cancer.
Via
Investor's Business Daily
Why Is Greenwave Tech Solutions (GWAV) Stock Down 53% Today?
March 19, 2024
Greenwave Tech Solutions stock is falling on Tuesday following an update on warrants for GWAV stock and other news this morning.
Via
InvestorPlace
Nvidia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
March 19, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Is Ontrak (OTRK) Stock Up 105% Today?
March 19, 2024
Ontrak stock is on the rise Tuesday as OTRK investors are excited about an upcoming live fireside chat set for later today.
Via
InvestorPlace
Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
March 19, 2024
Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash.
Via
Benzinga
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?
March 19, 2024
Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3.
Via
InvestorPlace
US Stocks Poised For Lower Open As Fed Jitters Dampen Tech Hopes; Oil Rally Pauses, Bitcoin Slides 8%
March 19, 2024
Interest-rate concerns seem to be impacting market sentiment as stock futures indicate a slightly lower opening on Tuesday.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 19, 2024
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning!
Via
InvestorPlace
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
7 Low-Cost Call Options With High-Profit Potential
February 19, 2024
Call options are exciting but they can be a bit confusing. Let me guide you to compelling opportunities among certain hot names.
Via
InvestorPlace
Fusion Pharmaceuticals - Already Discovered By Wall Street
February 06, 2024
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.
Via
Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
January 19, 2024
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.